Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease

被引:3
|
作者
Liu, Tso-Tsai [1 ,2 ]
Qiu, He [3 ]
Liu, Shi-Yu [4 ]
Chien, Chieh [2 ,5 ]
Wang, Jen-Hung [6 ]
Wong, Ming-Wun [1 ,2 ,7 ]
Yi, Chih-Hsun [1 ,2 ]
Lin, Lin [1 ,2 ]
Lei, Wei-Yi [1 ,2 ]
Liang, Shu-Wei [1 ,2 ]
Hung, Jui-Sheng [1 ,2 ]
Huang, Jee-Fu [8 ]
Chen, Chien-Lin [1 ,2 ,9 ]
Han, Ma Ai Thanda [3 ,10 ]
机构
[1] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med, Hualien, Taiwan
[2] Tzu Chi Univ, Hualien, Taiwan
[3] Rutgers New Jersey Med Sch, Dept Med, Div Gastroenterol & Hepatol, Newark, NJ USA
[4] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Nutr, Hualien, Taiwan
[5] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Rehabil Med, Hualien, Taiwan
[6] Hualien Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med Res, Hualien, Taiwan
[7] Tzu Chi Univ, Sch Postbaccalaureate Chinese Med, Hualien, Taiwan
[8] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
[9] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan
[10] Univ Arizona, Banner Univ Med Ctr, Dept Med, Div Gastroenterol & Hepatol, 1441 N 12th St,Rm 1080, Phoenix, AZ 85006 USA
来源
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES | 2022年 / 38卷 / 10期
关键词
fatty liver; lifestyle intervention; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; weight loss; CONTROLLED ATTENUATION PARAMETER; NONINVASIVE DIAGNOSIS; WEIGHT-LOSS; FIBROSIS; BIOPSY; VARIABILITY; CAP;
D O I
10.1002/kjm2.12580
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Metabolic-associated fatty liver disease (MAFLD) is a growing global problem associated with increasing obesity prevalence. Lifestyle modifications are currently recommended, including weight reduction, exercise, and diet control. This study evaluated the short-term effect of lifestyle modifications on transient elastography (TE) values in an obese population with MAFLD. Thirty-two MAFLD patients were recruited for this prospective study and all subjects participated in a 3-month program of lifestyle modification. Sequential demographic parameters and biochemical tests were compared before and after program completion. Liver fat and fibrosis changes were measured using TE with controlled attenuated parameter (CAP) and liver stiffness measurements (LSM). The mean age was 38.7 years old (10 males). The body weight (88.09 kg vs. 80.35 kg), body mass index (32.24 kg/m(2) vs. 29.4 kg/m(2)), waist (103.19 cm vs. 95.75 cm), and hip circumference (111.67 cm vs. 104.75 cm), and blood pressure (128/78 mmHg vs. 119/71 mmHg) significantly improved before and after the intervention, respectively. Aspartate aminotransaminase (24.06 U/L vs. 18.91 U/L), alanine aminotransaminase (33 U/L vs. 23.72 U/L), creatinine (0.75 mg/dl vs. 0.70 mg/dl), cholesterol (176.41 mg/dl vs. 166.22 m/dl), gamma-glutamyl transferase (26.59 IU/L vs. 19.81 IU/L), and low-density lipoprotein cholesterol (115.63 mg/dl vs. 103.19 mg/dl) also improved after the 3-month intervention. The average CAP significantly decreased after intervention (297.5 dB/m vs. 255.0 dB/m), however, no significant difference in LSM was observed (5.24 kPa vs. 4.82 kPa). The current study suggests that short-term lifestyle modification can effectively improve hepatic steatosis, and TE may serve as a monitoring tool for therapeutic intervention.
引用
收藏
页码:1012 / 1019
页数:8
相关论文
共 50 条
  • [1] Lifestyle Modifications Decrease Hepatic Steatosis in Taiwanese With Metabolic-Associated Fatty Liver Disease
    Qiu, He
    Liu, Tso-Tsai
    Wang, Jen-Hung
    Wong, Ming-Wun
    Yi, Chih-Hsun
    Lin, Lin
    Lei, Wei-Yi
    Hung, Jui-Sheng
    Chen, Chien-Lin
    Han, Ma Ai Thanda
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S1003 - S1003
  • [2] Urine Proteome in Distinguishing Hepatic Steatosis in Patients with Metabolic-Associated Fatty Liver Disease
    Liu, Chang-Hai
    Zheng, Shanshan
    Wang, Shisheng
    Wu, Dongbo
    Jiang, Wei
    Zeng, Qingmin
    Wei, Yi
    Zhang, Yong
    Tang, Hong
    DIAGNOSTICS, 2022, 12 (06)
  • [3] Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study
    Liu, Yuxiu
    Liu, Shiying
    Huang, Jiaofeng
    Zhu, Yueyong
    Lin, Su
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (05) : 938 - 945
  • [4] Metabolic-associated Fatty Liver Disease
    Zheng, Ming-Hua
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2021, 9 (06) : 793 - 794
  • [5] Quantitative US fat fraction for noninvasive assessment of hepatic steatosis in suspected metabolic-associated fatty liver disease
    Yin, Haohao
    Fan, Yunling
    Yu, Jifeng
    Xiong, Bing
    Zhou, Boyang
    Sun, Yikang
    Wang, Lifan
    Zhu, Yuli
    Xu, Huixiong
    INSIGHTS INTO IMAGING, 2024, 15 (01):
  • [6] Metabolic-Associated Fatty Liver Disease and Sarcopenia
    Bali, Triada
    Chrysavgis, Lampros
    Cholongitas, Evangelos
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) : 497 - 508
  • [7] Pathobiology of Metabolic-Associated Fatty Liver Disease
    Fouda, Sherouk
    Jeeyavudeen, Mohammed Sadiq
    Pappachan, Joseph M.
    Jayanthi, Venkataraman
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) : 405 - 416
  • [8] Lean Metabolic-Associated Fatty Liver Disease
    Gofton, Cameron
    Clark-Dickson, McCawley
    George, Jacob
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (03) : 431 - 444
  • [9] Alcohol and Metabolic-associated Fatty Liver Disease
    Sun, Fu-Rong
    Wang, Bing-Yuan
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2021, 9 (05) : 719 - 730
  • [10] Cardiovascular disease in metabolic-associated fatty liver disease
    Adams, Leon A.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2023, 30 (02) : 81 - 86